Company Description
McKesson Corporation provides healthcare services in the United States and internationally.
It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.
The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies.
The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services.
The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies.
The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada.
McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
| Country | United States |
| Founded | 1833 |
| Industry | Medical Distribution |
| Sector | Healthcare |
| Employees | 51,000 |
| CEO | Brian S. Tyler Ph.D. |
Contact Details
Address: 6555 State Highway 161 Irving, Texas 75039 United States | |
| Phone | 972-446-4800 |
| Website | mckesson.com |
Stock Details
| Ticker Symbol | MCK |
| Exchange | NYSE |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0000927653 |
| CUSIP Number | 58155Q103 |
| ISIN Number | US58155Q1031 |
| Employer ID | 94-3207296 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Brian S. Tyler Ph.D. | Chief Executive Officer and Director |
| Britt J. Vitalone | Executive Vice President and Chief Financial Officer |
| LeAnn B. Smith | Executive Vice President and Chief Human Resources Officer |
| Lori A. Schechter J.D. | Board and Enterprise Risk Advisor |
| Napoleon B. Rutledge Jr. | Senior Vice President, Controller and Chief Accounting Officer |
| Francisco Fraga | Executive Vice President, Chief Information Officer and Chief Technology Officer |
| Rachel Rodriguez | Vice President of Investor Relations |
| Michele Lau | Executive Vice President and Chief Legal Officer |
| Pete Slone | Senior Vice President of Corporate Public Affairs |
| Kirk Kaminsky | President of The US Pharmaceutical and Specialty Solutions Business |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 15, 2024 | 144 | Filing |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 144 | Filing |
| Feb 8, 2024 | 10-Q | Quarterly Report |
| Feb 7, 2024 | 8-K | Current Report |
| Jan 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 9, 2024 | 8-K | Current Report |
| Jan 3, 2024 | 144 | Filing |
| Nov 13, 2023 | 144 | Filing |
| Nov 7, 2023 | 8-K | Current Report |